464 related articles for article (PubMed ID: 23471651)
1. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
2. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
[TBL] [Abstract][Full Text] [Related]
3. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S
J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673
[TBL] [Abstract][Full Text] [Related]
4. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Pocathikorn A; Taylor RR; Mamotte CD
Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
9. Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Bjarnadottir O; Feldt M; Inasu M; Bendahl PO; Elebro K; Kimbung S; Borgquist S
Sci Rep; 2020 Jan; 10(1):558. PubMed ID: 31953433
[TBL] [Abstract][Full Text] [Related]
10. The role of HMGCR expression in combination therapy of simvastatin and FAC treated locally advanced breast cancer patients.
Yulian ED; Siregar NC; Sudijono B; Hwei LRY
Breast Dis; 2023; 42(1):73-83. PubMed ID: 36938720
[TBL] [Abstract][Full Text] [Related]
11. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Duncan RE; Lau D; El-Sohemy A; Archer MC
Biochem Pharmacol; 2004 Nov; 68(9):1739-47. PubMed ID: 15450939
[TBL] [Abstract][Full Text] [Related]
12. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
[TBL] [Abstract][Full Text] [Related]
13. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Kuwahara N; Sasaki S; Kobara M; Nakata T; Tatsumi T; Irie H; Narumiya H; Hatta T; Takeda K; Matsubara H; Hushiki S
Int J Cardiol; 2008 Jan; 123(2):84-90. PubMed ID: 17434618
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
[TBL] [Abstract][Full Text] [Related]
16. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
17. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
18. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
